Ming Xu, MD
Psychiatry · Bourbonnais, ILNPI 1548271018
Payments from drug & device makers
Across 842 payments — averaging $600.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$244K
- Axsome Therapeutics, Inc.$55K
- Supernus Pharmaceuticals, Inc.$49K
- Alkermes, Inc.$35K
- E.r. Squibb & Sons, L.L.C.$32K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$32K
- plus $59K from 19 others
What the payments were for
- Consulting fees$40,1558%
- Speaking & faculty fees$428,59885%
- Travel & lodging$21,5774%
- Food & beverage$14,8533%
- Education$400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 372 | $243,603 |
| Axsome Therapeutics, Inc. | 61 | $55,241 |
| Supernus Pharmaceuticals, Inc. | 83 | $48,617 |
| Alkermes, Inc. | 50 | $34,529 |
| E.r. Squibb & Sons, L.L.C. | 46 | $32,244 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 41 | $31,587 |
| Vanda Pharmaceuticals Inc. | 45 | $24,124 |
| Teva Pharmaceuticals USA, Inc. | 28 | $17,631 |
| Corium, LLC | 15 | $8,621 |
| Idorsia Pharmaceuticals US Inc | 7 | $7,466 |
| Sunovion Pharmaceuticals Inc. | 38 | $322 |
| Otsuka America Pharmaceutical, Inc. | 10 | $300 |
| Johnson & Johnson | 11 | $192 |
| Biogen | 8 | $179 |
| Microvention, Inc. | 1 | $117 |
| Eisai Inc. | 7 | $104 |
| Lundbeck LLC | 6 | $95 |
| Merck | 3 | $53 |
| Boston Scientific | 1 | $51 |
| Almatica Pharma LLC | 3 | $40 |
| Bausch Health US, LLC | 2 | $39 |
| Indivior Inc. | 1 | $21 |
| Neurocrine Biosciences, Inc. | 1 | $17 |
| Ironshore Pharmaceuticals Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$238,391
- LYBALVI$132,849
- Auvelity$53,788
- QELBREE$47,071
- COBENFY$31,127
- CAPLYTA$30,971
- Fanapt$23,437
- UZEDY$16,912
- Azstarys$8,409
- QUVIVIQ$7,351
- ARISTADA$983
- VIIBRYD$200
- WEB Aneurysm Embolization System$117
- Sofia 6F-125cm STR$117
- HydroSoft 3D$117
How this compares
$505,223 in reported general payments places this provider in the 95th percentile of 1,344 psychiatry providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 396 | $539,529 |
| LybalviOlanzapine/Samidorphan Malate | 142 | $124,191 |
| IngrezzaValbenazine Tosylate | 14 | $112,975 |
| Abilify MaintenaAripiprazole | 31 | $83,427 |
| Invega SustennaPaliperidone Palmitate | 31 | $77,701 |
| FanaptIloperidone | 27 | $63,214 |
| CaplytaLumateperone Tosylate | 41 | $60,738 |
| UzedyRisperidone | 17 | $54,890 |
| TrintellixVortioxetine Hydrobromide | 57 | $35,346 |
| Lurasidone Hcl | 73 | $33,180 |
| Clozapine | 372 | $25,832 |
| RexultiBrexpiprazole | 12 | $19,290 |
| Aripiprazole | 238 | $18,790 |
| BelsomraSuvorexant | 31 | $13,067 |
| AuvelityDextromethorphan Hbr/Bupropion | 20 | $10,638 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Fetzima | $243,603 | $545,392409 claims |
| Alkermes, Inc.Lybalvi | $34,529 | $124,191142 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $17 | $112,97514 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $300 | $102,71743 claims |
| Johnson & JohnsonInvega Sustenna, Risperdal | $192 | $81,25844 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $24,124 | $63,21427 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $31,587 | $60,73841 claims |
| Teva Pharmaceuticals USA, Inc.Uzedy | $17,631 | $54,89017 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $12 | $44,20280 claims |
| MerckBelsomra | $53 | $13,06731 claims |
| Axsome Therapeutics, Inc.Auvelity | $55,241 | $10,63820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,344 psychiatry providers in Illinois.
Other psychiatry in Bourbonnais
- Jeffrey RossNorthbrook$10.8M
- Yuhwen ChowChicago$8.5M
- Mark LermanNorthbrook$4.5M
- Danesh AlamWinfield$2.7M
- John ZajeckaSkokie$2.5M
- Riaz BaberNaperville$2.4M
- Michael GreenbaumLibertyville$2.2M
- Sandeep GaonkarNaperville$1.8M
- Jon GrantChicago$1.4M
- David KempOak Lawn$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.